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Abstract: Background and Aims: Due to increasing knowledge of the “gut–liver axis”, there has been
growing interest regarding the use of fecal microbiota transplant in the management of chronic liver
disease. There are limited data available and current guidelines are mostly based on expert opinions.
We aim to perform the first systematic review investigating safety and efficacy of fecal microbiota
transplant particularly among high-risk decompensated cirrhosis patient populations. Methods:
Literature search was performed using variations of the keywords “fecal microbiota transplant”
and “cirrhosis” on PubMed/Medline from inception to 3 October 2021. The resulting 116 articles
were independently screened by two authors. In total, 5 qualifying studies, including 2 randomized
control trials and 3 retrospective case series, were found to meet established eligibility criteria and
have adequate quality of evidence to be included in this review. Results: Of the total 58 qualifying
patients, there were 2 deaths post fecal microbiota transplant, 1 of which could not rule out being
related (1.7%). Among the remaining 56 participants, 8 serious adverse events were reported, of
which 2 could not rule out being related (3.6%). The success rate of fecal microbiota transplantation
in treating recurrent Clostridioides difficile infection among patients with decompensated cirrhosis
was 77.8%. The success rate when used as investigational treatment for hepatic encephalopathy was
86.7%, with multiple studies reporting clinically significant improvement in encephalopathy testing
scores. Conclusions: We found a marginally higher rate of deaths and serious adverse events from
fecal microbiota transplant in our patient population compared with the average immunocompetent
population, where it was previously found to have 0 deaths and SAE rate of 2.83%. The efficacy when
used for recurrent C. difficile infection was 77.8% and 87% in the decompensated cirrhotic and general
populations, respectively. Studies on efficacy in novel treatment of hepatic encephalopathy have been
promising. This study concludes that fecal microbiota transplant use in decompensated cirrhosis
patients should be used with caution and preferably be limited to research purposes until better data
are available.

iations.

Keywords: fecal microbiota transplant; decompensated cirrhosis; Clostridioides difficile infection;
hepatic encephalopathy
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1. Introduction
Fecal microbiota transplantation (FMT) is a novel and growing field with expanding
therapeutic potential. Limitations to widespread FMT use despite promising outcomes is
likely due to the lack of large, well-designed studies; one such example is the use of FMT
in cirrhotic patients. In recent years, the therapeutic role of FMT in the cirrhotic population
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has become more prominently discussed, as new research hypothesizes that underlying
intestinal dysbiosis may play a fundamental role in worsening clinical status in such
patients [1–5]. Although the pathogenesis is still unclear, new research hypothesizes that
“portal hypertension, reduced secretion of gastric acid, impaired gastrointestinal motility,
and local and systemic immunological dysfunction” are the primary factors contributing to
gut microbiota derangements that lead to increase in pathogenic bacteria and decrease in
commensal bacteria [2]. This further causes inflammation and damage along the intestinal
membrane, allowing for translocation of bacteria and bacteria-derived byproducts such
as ammonia which can further trigger liver injury and systemic inflammation and can
lead to decompensation in cirrhotic patients such as hepatic encephalopathy [3]. The term
“gut–liver axis” represents the intricate relationship and co-dependence between the gut
microbiome and the liver [1]. By altering the composition of the gut microbiota, FMT
can potentially prevent, treat, and/or curtail the severity of the decompensation event.
Increase in research efforts in and improved understanding of the gut–liver axis has led to
renewed discussion about the potential therapeutic uses of FMT in patients with chronic
liver disease.
Yet, before further large studies can be undertaken it is imperative to determine the
safety of FMT in this patient population, specifically in decompensated cirrhotics who have
the highest associated risk and mortality [4]. There is currently very limited published
data and no systematic reviews regarding the safety of FMT in decompensated cirrhotics
as these patients are often excluded from most FMT studies due to safety concerns. In
the joint British Society of Gastroenterology (BSG) and Healthcare Infectious Society (HIS)
guidelines—published in 2018 and considered the most comprehensive evidence-based
recommendations for practicing clinicians—the authors concluded that “FMT should be offered with caution to patients with Clostridioides difficile infection (CDI) and decompensated
chronic liver disease” with very low grade of evidence and weak strength of recommendation [6]. In other words, any estimate of effect is uncertain due to lacking not only published
evidence but even consensus among multidisciplinary expert opinions [6]. Recently, our
research team conducted a systematic review that found that FMT can be a safe and effective treatment of hepatic encephalopathy (HE) and CDI in cirrhotic patients [7]. However,
the review did not delineate between patients with compensated and decompensated
cirrhosis [7]. Hence, in this study, we aim to perform the very first systematic review
regarding safety and efficacy outcomes of FMT in decompensated liver disease.
2. Methods
2.1. Search Strategy
We performed a comprehensive literature search using variations of the keywords
“fecal microbiota transplant” and “cirrhosis” including MeSH terms to identify original
studies published in PubMed/Medline from inception through 3 October 2021. The systematic review was performed on studies published prior to 3 October 2021. Results were
limited to human studies published in English. There was a total of 116 studies for review.
See Supplemental Table S1 for detailed search terms.
2.2. Eligibility Criteria
Inclusion criteria: (1) FMT for various indications; (2) decompensated cirrhosis defined
as stage 4 fibrosis with Child–Turcotte–Pugh (CTP) C, or a major complication including variceal hemorrhage, large ascites, spontaneous bacterial peritonitis (SBP), hepatic
encephalopathy (HE), hepatocellular carcinoma, hepatorenal syndrome, and hepatopulmonary syndrome; (3) reporting of patient data and outcomes after first fecal infusion;
(4) adult patients (≥18 years old) of any sex; (5) minimum follow-up of 1 month; and (6) at
least moderate quality of evidence.
Exclusion criteria: (1) individual case reports which reflect unique cases and significant
bias; (2) studies available only as abstracts; (3) studies without patient data; (4) non-English
studies; (5) animal studies; and (6) patients younger than 18 years of age.
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Table 1. Summary of included studies.
Author/Year

Bajaj 2017 * [8]

Study Design

RCT

Quality
Assessment

RoB 2

Quality Score

8

Dates

10/2015–7/2016

Sample Size

20

# Pts FMT

10

Follow-up Period

Pt qualifications

HE

Open-biome
capsule

Recurrent,
severe CDI

Capsule
Colonoscopy
PEG

Hepatitis C
virus, alcohol,
Non-Alcoholic
SteatoHepatitis,
others
Alcohol,
Non-alcoholic
steatohepatitis,
Hepatitis C
virus

Active EtOH,
positive CDI, on
immunosuppressive or
antimicrobial

HE

Colonoscopy

Alcohol,
Hepatitis C
virus

None

Recurrent
severe CDI

Colonoscopy
or NG tube

7/2017–5/2018

20

10

5 months

Cheng 2020 [10]

Retro-spective
study

NIH quality
assessment

9

1/2012–11/2018

63

24 #

12 weeks

Decompensated
cirrhosis (ascites,
varices, variceal
hemorrhage, HE)

NIH quality
assessment

Enema

Hepatitis C
virus,
Non-alcoholic
steatohepatitis,
alcohol, others

8

Case series

HE

5 months

RoB 2

Olmedo 2019 [12]

FMT Method

Hepatitis C
virus,
Non-alcoholic
fatty liver
disease,
alcohol, others

RCT

Case series

Indication for
FMT

Age > 18,
cirrhosis with
recurrent HE
at least
2 documented
episodes
requiring therapy

Bajaj 2019 * [9]

Mehta 2018 [11]

Exclusions
MELD > 17,
allergies to pre
FMT abx,
antimicrobials,
immunosuppressive, CDI,
pregnancy, EtOH,
unable to give
informed consent
MELD > 17,
unable consent,
current abx,
contraindication
to endoscopic
procedure
Patients with
<12 week follow
up and history of
liver
transplantation

Cirrhosis w
recurrent HE at
least 2 episodes
within last year
on lactulose
and rifaximin

NIH quality
assessment

Etiology Cirrhosis

7

8/2017–10/2017

10

10

20 weeks

8

2013–2017

4

4 **

4–11 months

Hepatic
encephalopathy
more or equal to
2 episodes of
grade 2–4 HE in
last 6mo
Cirrhosis (CP C
or esophageal
varices bleeding)
and CDI

RCT = Randomized controlled trial; RoB 2 = Revised Cochrane risk-of-bias tool; HE = Hepatic encephalopathy; MELD = Model for End-Stage Liver Disease; FMT = Fetal microbiota
transplantation; CDI = Clostridioides difficile infection; EtOH = Ethanol; NIH = National Institutes of Health; PEG = Percutaneous endoscopic gastrostomy; NG = Nasogastric. * Bajaj 2017
and Bajaj 2019 patient data is published in multiple other follow up studies. The first published versions were chosen to be included in this study as they were adequate to fulfill this
study’s eligibility requirements and provided most information regarding the study population’s cirrhosis status. # Although the total number of patients who received FMT in Cheng
2020 was 63, only 24 patients were diagnosed with decompensated cirrhosis. ** One patient expired before the efficacy profile associated with FMT could be evaluated.

Antibiotics 2022, 11, 838

5 of 11

2.4. Study Outcomes
The primary endpoint was safety of FMT in decompensated cirrhosis patients in terms
of death and serious adverse events (SAE) occurring within 30 days after FMT. SAEs were
defined as death or any event requiring hospitalization. Adverse events were further
determined to be more likely or unlikely to be related to FMT. Thirty days was chosen as
the latest time an adverse event could still be reasonably attributed to the original fecal
transplantation [7].
The secondary endpoint was the efficacy of FMT. When used for CDI, FMT success was
defined as the absence of symptoms (≥3 loose bowel movements in ≤24 h) with positive
CDI confirmatory stool testing within 8 weeks of treatment [13]. When used for HE, FMT
success was defined by no recurrence of HE at follow-up and improvement in scores on
objective testing (Encephalapp Stroop test or Psychometric Hepatic Encephalopathy Score
(PHES)). PHES has previously been established to be the gold standard for the diagnosis of
HE [14]. It tests for skills such as attention, and psychomotor function [15]. It is composed
of five component tests: number connection test-A, number connection test-B, serial dotting
test, line tracing test, and digit symbol test [14]. A score lower than −4 has been found to
be associated with HE and poorer cognitive performance [14]. EncephalApp Stroop test is
a validated App-based version of the Stroop test [15]. Similarly to PHES, the Stroop test
also evaluates cognitive flexibility and psychomotor speed [16]. It consists of two stages:
the “ON” stage where the participant names the color of the pound signs, and the “OFF”
stage where the participant states the color of a discordant word [16]. If the time taken
for both ON and OFF stages is longer than 269.8 s, it has been determined with sufficient
sensitivity and specificity that a diagnosis of HE can be made [15,16].
We then referred to and compared our outcomes with those from previously published
articles that studied the efficacy and safety profiles of FMT in various populations such
as general population, immunocompetent cohort, immunocompromised patients, and
cirrhotic patients.
2.5. Quality Assessment
Revised Cochrane risk-of-bias tool (RoB 2) was used to evaluate the methodological
quality of randomized controlled trials (RCT). RoB 2 is a revised version of the original
Cochrane risk-of-bias tool that has been widely used in systematic reviews [17]. The tool
consists of five domains: randomization process, derivations from intended interventions,
missing outcome data, measurement of the outcome, and selection of the reported result.
The overall risk of bias for each RCT is determined high, low, or some concern based on the
individual elements in the 5 domains [17].
For case series, observational and cohort studies, appraisal of quality and risk of bias
was performed by a series of quality assessment tools developed by US National Heart
Lung and Blood Institute (NHLBI) of National Institutes of Health (NIH) (https://www.
nhlbi.nih.gov/health-topics/study-quality-assessment-tools) (accessed on 14 March 2022).
A set of question items with Yes/No answers were used, with a “Yes” counting as a score
of 1 and a “No” as a score of 0. In the tool used for case series, there were a total of 9
questions. A score of 7–9 corresponds to good quality, while scores of 4–6 and 1–3 indicate
moderate and poor quality, respectively [18]. On the other hand, for observational and
cohort studies, there were 14 items in total [18]. However, three items were not applicable
to the studies included in our systematic review. Out of the available 11 points, studies that
score 7–11, 4–6, and 1–3 were graded as good, moderate, and poor quality, respectively [18].
In the final selection stage, only studies with at least moderate level of evidence were
included. Quality appraisal was performed by two independent authors (K.M.T. and K.B.).
If there was any disagreement, a third reviewer (A.S.H.) evaluated the article and achieved
consensus through discussion. See Supplemental Tables S3–S5 for quality assessment scores
for each study.
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3. Results
Table 1 presents a summary of the 5 multi-patient studies included for final analysis
in this systematic review, composed of 2 randomized control trials and 3 retrospective
case series with a total of 58 patients [8–12]. All had decompensated cirrhosis as defined
above and received FMT. Etiology of cirrhosis ranged from alcohol, chronic Hepatitis C
virus, metabolic associated fatty liver disease, primary sclerosing cholangitis, and others.
In 28 patients, FMT was given per guideline for recurrent/severe CDI; however, only
27 were included in the review of efficacy. One patient expired seven days later from
cholangitis which did not meet our inclusion criteria of evaluating the efficacy of FMT
within 8 weeks. This patient, however, was still included in the evaluation of the safety
profile of FMT. In 30 patients, FMT was given for refractory HE as an investigational therapy.
Two studies were from the United States [8,9], one each from India [11] and Spain [12],
and one was a multinational study from the United States, Canada, and Italy [10]. In
the study by Cheng et al., 24 of the 63 patients were considered to have decompensated
cirrhosis. Thus, the overall total number of patients in our review was 58 patients. The
total number of patients included in the efficacy review was 57, while that for safety review
was 58. Multiple FMT delivery methods are used, including via nasogastric tube (n = 1),
enema (n = 10), colonoscopy (n = 13), and capsule (n = 10). Cheng et al. described the
methods of FMT administration as capsule (n = 3), colonoscopy (n = 59), and percutaneous
endoscopic gastrostomy (PEG) tube (n = 1) but did not differentiate between cirrhotic and
decompensated cirrhotic patients.
Table 2 describes adverse outcomes. There was a total of 2 deaths post FMT, 1 of which
could not exclude being related to FMT (1/58). This occurred in a patient with known
choledocholithiasis and recurrent cholangitis who developed severe cholangitis 7 days
post FMT. Although it is difficult to determine if the cause of death was related to FMT
or the patient’s prior history, translocation of bacteria from FMT could be theoretically
possible. The second death was a patient with diagnosis of alpha 1 antitrypsin deficiency
who developed bronchopneumonia 2 months post FMT, which was deemed to be unrelated
to FMT. Among the remaining 56 participants, 8 SAE were reported of which 2 could not
rule out relation to FMT (2/56). One patient developed Escherichia coli bacteremia 3 days
post FMT without any other documented causes, which is likely to be related to FMT. One
patient developed SBP in week 4, which was considered to still be possibly related to initial
FMT. The remaining reported 4 SAEs were deemed unlikely to be related to FMT, including
SBP at week 8, bleeding portal hypertensive gastropathy at day 23, hospitalization for HE
at day 56, acute renal failure at day 85, and chest pain at day 1115 post FMT.
Table 3 shows the secondary outcome of FMT efficacy. Of the 27 decompensated
cirrhotic patients who received first time FMT for severe or recurrent CDI and were followed
for at least 8 weeks, 6 patients had recurrence of CDI at 8-week follow up (success rate
21/27 = 77.8%). One patient received FMT for CDI resulting in death from cholangitis
at 2 weeks, and was excluded from the efficacy review as adequate follow-up endpoint
was not met. Of the 30 patients who received FMT for HE, 4 patients had recurrence
of HE at time of follow-up, which did range from 20 weeks to 5 months (success rate
26/30 = 86.7%). Of note, one of these patients receiving FMT for HE also resulted in
death at 2 months which was deemed adequate for efficacy review. In Bajaj 2017, FMT
patients had significantly fewer HE episodes (0% vs. 50%; p = 0.03) and PHES improvement
(−3.1 vs. 0.00; p = 0.01) at 5 months compared to patients receiving standard of care (SOC),
with PHES score improvement [8]. In Bajaj 2019, patients who received FMT had a clinically
significant improvement in Encephalapp performance compared to those receiving SOC
(p = 0.02) [9]. In Mehta 2018, patients with HE receiving FMT had a statistically significant
reduction in CTP score 9.5 (9–10.75) vs. 8 (7–8) and MELD 18 (16.25–19) vs. 15 (14–16) [11].
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Table 2. Adverse event outcomes.
Study

Death

SAE

AE

Unrelated

Bajaj 2017 [8]

None

None

Unknown

2– day 85 for AKI and
day 1115 for chest pain
was neg ACS

None

1 UTI from Klebsiella
pneumoniae 2 months
post; 1 pneumonia and
receiving alpha 1
antitrypsin infusions

1– post TIPS
complication HE not
related to FMT

Bajaj 2019 [9]

None

Cheng 2020 [10]

None

None

Unknown

2– bleeding portal
hypertensive
gastropathy 23 days
after FMT; hepatic
encephalopathy
56 days after FMT

Mehta 2018 [11]

1– bronchopneumonia
2 months after FMT

1– SBP at week 4

Unknown

1– SBP at week 8

Olmedo 2019 [12]

1– death 7 days post
FMT from cholangitis

1– Escherichia. Coli
bacteremia 3 days post
FMT without other
cause

Unknown

None

SAE = Serious adverse events; AE = Adverse events; AKI = Acute kidney injury; ACS = Acute coronary syndrome;
UTI = Urinary tract infection; TIPS = Transjugular intrahepatic portosystemic shunt; HE = Hepatic encephalopathy;
FMT = Fecal microbiota transplantation; SBP = Spontaneous bacterial peritonitis.

Table 3. Efficacy outcomes.
Study

Bajaj 2017 [8]

Bajaj 2019 [9]

Cheng 2020 [10]

Mehta 2018 [11]

Olmedo 2019 [12]

Indication for FMT

HE

HE

Recurrent, severe,
fulminant CDI

HE

Recurrent severe CDI

Definition of efficacy

Outcome

No recurrence of HE

significant less HE episodes at
5 months (0% vs. 50% p = 0.03);
PHES score improvement (−3.1
vs. 0.00 p = 0.01); MELD score no
clinically significant difference
(0.78)

EncephalApp and no
recurrence of HE

EncephalApp performance
improved post FMT only
(p = 0.02); 3 patients had no
recurrence of HE. 1 patient had
HE recurrence

No recurrence of CDI

18 out of 24 patients with
decompensated cirrhosis who
received FMT had resolution of
CDI. 6 patients had recurrent CDI
at follow up

No recurrence of HE, CTP,
MELD

7 out of 10 patients had no
recurrence of HE; statistically
significant reduction in CTP score
(9.5 9–10.75) vs. 8 (7–8) and MELD
18 (16.25–19) vs. 15 (14–16)

Not well defined

3 out of 3 patients had resolution
of CDI. 1 patient expired from
cholangitis within 7 days of FMT
and was excluded from
efficacy review

FMT = Fecal microbiota transplantation; HE = Hepatic encephalopathy; PHES = Psychometric Hepatic Encephalopathy Score; MELD = Model for End-Stage Liver Disease; CDI = Clostridioides difficile infection.
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4. Discussion
In our study, we found that the overall rate of death possibly attributable to FMT was
1.72% (1/58) with the rate of other SAEs attributable to FMT as 3.57% (2/56). In contrast,
the systematic review on cirrhotic patients by Tun et al. demonstrated that overall death
rate was 1.57% (2/127), and the number of SAEs and AEs were 9.45% (12/127) and 19.68%
(25/127), respectively [7]. The data suggests that hepatic decompensation may not be
correlated with or attributable to SAEs or AEs. We compared our data with a meta-analysis
conducted by Michailidis et al. that studied high quality randomized controlled trials and
included all patients receiving FMT without factoring in comorbid conditions to represent
the baseline population [19]. In this study, death had to be directly attributed to FMT or
peri procedural [19]. Serious adverse drug experiences were defined as those that result in
death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation
of existing hospitalization, a persistent or significant disability/incapacity, or a congenital
anomaly/birth defect during the follow up 30 days after FMT [19]. This study of the
general population found 0 deaths (0/388) and rate of total SAEs to be 2.83% (11/388)
which is comparable in terms of safety data to our study population [19]. A separate large
but single center study was conducted by Youngster et al., regarding use of FMT to treat
CDI in the general population [20]. There were no SAEs; AEs were reported in 30% of
patients [20]. In a meta-analysis by Shogbesan et al. of 44 non-randomized studies of FMT
in an immunocompromised population (patients on immunosuppressant medications, with
human immunodeficiency virus (HIV), inherited or primary immunodeficiency syndromes,
cancer undergoing chemotherapy, or organ transplant, including bone marrow transplant),
the overall rate of death was 0.66% (2/303) due to aspiration and pneumonia; rate of serious
adverse events leading to hospitalization was 8.3% (25/303) [21]. The authors concluded
that the overall rates of SAEs in the immunocompromised patients were similar to those in
the immunocompetent population [21]. Overall, the rate of death in our study population
was slightly higher compared to that in Shogbesan’s study population, although the rate of
SAEs remained lower.
In terms of efficacy data for CDI, we found that the rate of success for first time FMT
treatment in the decompensated cirrhotic patient population was 77.8% (21/27), which
is lower than previously reported data such as a randomized control trial by Cammarto
et al. where efficacy was 90% [22]. Of note, in Shogbesan’s study of immunocompromised
patients, the efficacy was found to be 207/234 (87%), comparable to a normal immunocompetent population [21]. Therefore, the overall efficacy of first FMT in CDI in our patient
population was lower than the general as well as the immunocompromised population,
although it still remains high overall. In comparison, success rate for treatment of CDI
among cirrhotic patients was 86% (82/95) [7]. The lower rate of cure in our study indicates
that decompensation may hinder the therapeutic potency of FMT in treating CDI. Such
patients may need multiple doses of FMT for resolution of CDI. The findings from our study
are also consistent with the results from Shogbesan’s study; it was discovered that patients
with a single immunocompromising element achieved a higher success rate of treatment
than those with multiple immunodeficiencies (p < 0.001) [21]. It has been noted that a
patient’s immune status may determine the number of doses required or the success rate for
FMT [7]. Indeed, Shogbesan et al. discovered that immunocompromised patients required
more than one dose of FMT to achieve cure and that the success rate improved from 88% to
93% with multiple FMTs [21]. With cirrhosis already being an immunocompromising factor,
decompensation may exacerbate the deficiencies in the immune status and may lessen the
efficacy of FMT. This could be a reason that the decompensated cirrhotic patient population
had a lower success rate than the cirrhotic patients, other immunocompromised patients,
or the general population. Hence, it is crucial to take decompensation into consideration
while considering FMT for treatment of CDI and to counsel patients on potential reduced
effectiveness and/or need for multiple administrations. It may be necessary to address the
decompensation prior to proceeding with FMT.
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FMT also appears to be effective in HE. Our review demonstrates that an improvement
in cognitive tests (PHES and EncephalApp Stroop test) or reduced recurrence of HE was
seen across all the studies compared to SOC. Furthermore, the effect of FMT was maintained
over the course of the year. Similar findings were reported in the previous systematic review
on cirrhotic patients [7]. A similar finding was corroborated by Bloom et al. Among cirrhotic
patients with HE, PHES improved by 2.1 points after three doses of FMT and by 2.9 points
after five doses [23]. Furthermore, overall PHES remains improved by 3.1 points 4 weeks
after the fifth dose of FMT [23]. In comparison, improvement in the Stroop test was seen
only with five doses of FMT [23].
5. Limitations
The primary weakness of this study is due to the lack of published literature with
direct patient data on FMT use in cirrhosis patients. Due to the limited number as well as
the fact that efficacy was often reported but was not the primary endpoint in these studies,
a true meta-analysis was unable to be performed. Two of our strongest studies included
were by the same research group, and although two separate selection processes of patients
were used and made up most of the data for use of FMT in treating HE. Due to the nature
of this systematic review, we were unable to control for confounding factors or variables
both in the patient qualities and in the procedural protocols (method of FMT, type of FMT
given). Additionally, AEs and SAEs were reported by the original authors as related or
unrelated to FMT based on DSMB guidelines (Data and Safety Monitoring Board). Since
we were not able to obtain the original data of the studies, it is possible that the number
of adverse events attributable to FMT may be inaccurate. Lastly, after an initial search on
multiple databases and exclusion of articles that did not meet the inclusion criteria, it was
noted that the results were largely identical. Therefore, only PubMed/Medline was used to
retrieve qualifying articles for further review as it is the largest and most robust database,
which may not have extracted smaller studies and may have introduced publication bias.
6. Conclusions
Based on available literature, we found that there may be a marginally higher rate
of death and SAE from FMT in decompensated cirrhosis compared with the average
immunocompetent population. When used for CDI, the efficacy of one-time infusion was
also found to be less effective. New data does appear to support a therapeutic advantage
of FMT compared with SOC in hepatic encephalopathy. We conclude that although FMT
is likely to be a valuable tool in the future management of cirrhosis patients, its use in
decompensated cirrhosis patients should be used with caution and preferably limited to
research purposes until better safety and efficacy data is available. Although this study
was confined by paucity of published data and inability to perform a true meta-analysis, it
does highlight the need for more robust randomized controlled studies regarding FMT in
this specific patient population in the future.
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